Tuesday, June 9, 2026
The decarbonisation of pharmaceutical manufacturing enters a new phase
LCA
A pilot project launched in Dijon by Delpharm, in collaboration with academic partners, offers a concrete illustration of how sustainability is evolving within the pharmaceutical industry.
The initiative, ACVmed, focuses on measuring and reducing the carbon footprint of a drug manufacturing process using a full Life Cycle Assessment (LCA) methodology. While LCA is not new, its application at process level, with the objective of identifying actionable levers for decarbonisation, marks a significant step forward.
For years, sustainability strategies in pharma have largely relied on estimations and high-level commitments. What projects like ACVmed highlight is a shift towards something more demanding: a detailed understanding of physical and energy flows across the entire lifecycle of a product, from raw materials to end-of-life.
This evolution reflects a broader industry transition.
Decarbonisation is no longer a question of intent, but of execution. Measuring accurately, identifying hotspots, and prioritising concrete actions are becoming essential capabilities for pharmaceutical manufacturers.
Another key dimension of the project lies in its focus on training and knowledge transfer. By developing tools and educational content for industrial teams, ACVmed acknowledges a critical reality: sustainable transformation cannot happen without embedding new competencies within organisations.
Beyond the initiative itself, this type of project also illustrates the growing importance of collaboration between industry, academia and regional ecosystems in addressing complex sustainability challenges.
For the pharmaceutical sector, the implications are clear. The next phase of decarbonisation will be operational, data-driven, and deeply integrated into industrial processes.
At The Pharma Sustainability Days, these questions are increasingly central. As more companies move from commitments to implementation, the need for shared methodologies, feedback from real-world applications, and cross-industry dialogue continues to grow.
Initiatives such as ACVmed do not just demonstrate progress: they help define what effective action looks like.